Rustor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rustor

Property Description
Active ingredient Rosuvastatin Calcium
Form Oral film-coated tablet or capsule
Pharmacological class HMG-CoA reductase inhibitor (Statin)
General purpose Lipid-lowering agent
Origin Synthetic compound

What Type of Medicine is Rustor?

Rustor is a synthetic, prescription-only medication that is defined by its active ingredient, Rosuvastatin Calcium, and belongs to the pharmacological class known as Statins. The active compound, Rosuvastatin, is chemically prepared as the calcium salt. This classification places the medicine squarely within the HMG-CoA reductase inhibitor group, signifying its primary function is to modify the systemic production of cholesterol. Rustor, as a specific commercial preparation, is clinically recognized for its high potency compared to some older agents in the Statin class.

The Active Ingredient and Physical Form

Rustor is a single-ingredient product designed for oral administration, commonly presented as a film-coated tablet or capsule. The medication contains only Rosuvastatin Calcium as the therapeutic agent, distinguishing it as a specific, non-combination formulation. The film-coated tablet form is designed for ease of ingestion and predictable release, ensuring consistent delivery of the Rosuvastatin compound, which is engineered for selective action primarily in the liver. This solid dosage form and oral route ensure the systemic absorption necessary for effective pharmacotherapy targeting lipid levels.

General Therapeutic Purpose and Benefit

The general purpose of Rustor is to correct and stabilize imbalances in the blood lipid profile by efficiently reducing harmful cholesterol levels. By performing selective HMG-CoA reductase enzyme blockage, the drug inhibits the body's internal synthesis of cholesterol. This primary action results in a substantial reduction of circulating Low-Density Lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol. Statins, like Rosuvastatin, are highly effective in lowering LDL-C levels, which is a key factor in reducing cardiovascular risk. This indicates the drug's importance in managing high cholesterol and aiding in atherosclerosis prevention. A typical scenario involves using Rustor as part of a long-term plan to maintain healthy lipid levels in adults diagnosed with hypercholesterolemia.

Regulatory References

  1. NIH: Rosuvastatin - StatPearls

What side effects are possible with Rustor?

Possible Side Effects and Safety Information

This information details the high-level safety profile and adverse reactions for Rosuvastatin Calcium (Rustor), as documented in official government regulatory labels. It is not instructional and does not contain clinical advice or dosing information.


Officially Classified Adverse Reactions

The most frequently reported adverse reactions, according to clinical trial data, typically affect the nervous, gastrointestinal, and musculoskeletal systems. Common documented reactions include headache, myalgia (muscle pain), nausea, constipation, and general asthenia (weakness).

System-Organ Class Examples of Documented Effects
Musculoskeletal Myalgia, Arthralgia, Rhabdomyolysis
Hepatobiliary Hepatic Dysfunction, Elevated Serum Transaminases
Nervous System Headache, Dizziness, Cognitive Impairment

Serious Adverse Reactions and Key Constraints

The official safety documents emphasize the risk of rare but serious adverse reactions, notably Rhabdomyolysis, which involves severe muscle breakdown and can lead to acute kidney injury, and rare reports of Fatal and Non-fatal Hepatic Failure.

Specific safety considerations are formally documented for certain populations. The medicine is contraindicated during pregnancy and lactation, and in patients with active liver disease. Patients with renal impairment or who are geriatric (age 65 years or greater) are explicitly identified as having an increased risk for musculoskeletal complications, such as myopathy, according to official labeling. Furthermore, the risk of myopathy is stated to be greater with the highest approved dosage.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information establishes that there is no specific treatment or antidote available in the event of an overdose of Rustor.

Documented Overdose Presentations

Clinical experience with overdosage is limited. The primary concern is the potential for exacerbation of the most serious effects known to be associated with this drug class, specifically rhabdomyolysis (severe muscle breakdown) and hepatic dysfunction (liver injury).

Physiological systems affected that require monitoring include the musculoskeletal system (creatine kinase or CK levels) and liver function (serum transaminase levels). Haemodialysis is not anticipated to be an effective treatment method.

Required Emergency Actions

If an overdose is suspected, seek immediate medical attention or call emergency services right away, even if the individual has no noticeable symptoms. All overdose cases must be treated symptomatically, and supportive care measures must be instituted as required by clinical judgment.

Monitoring and supportive management include:

  • Monitoring of liver function tests and creatine kinase levels must be performed.
  • Maintenance of vital functions and treatment of symptoms as they arise.

All patients with known or suspected overexposure require prompt professional assessment and observation.

Therapeutic Uses of Rustor

What Rustor Treats: Main Uses and Benefits

Rustor is primarily used for the supportive management of symptoms that interfere with daily functioning and create noticeable physiological strain. The medication is commonly used when short-term symptomatic assistance is needed during periods when symptoms are heightened or disruptive. This type of symptomatic relief is considered relevant in clinical settings involving acute or unstable symptom patterns.


Supportive Relief for Acute Discomfort

Rustor helps manage symptom clusters that may become intense or disruptive during flare-ups. It is often applied during phases of increased distress or discomfort when symptoms intensify and supportive relief is needed. It plays a role in managing symptoms that appear suddenly or fluctuate, and supports the patient during periods of heightened physiological stress.

The medicine is relevant in conditions characterized by periods of heightened symptoms, conditions involving episodic or fluctuating manifestations, and conditions marked by increased physiological stress. It contributes to improved day-to-day comfort during symptomatic periods and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Assistance with Episodic Symptoms

Rustor may assist with maintaining a sense of stability when symptoms are more noticeable, and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus on Symptomatic Relief

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Rosuvastatin

The eligibility for Rosuvastatin (Rustor) is strictly defined by government regulatory documents, which establish certain absolute contraindications and conditions for restricted use.

Must Not Use (Contraindicated Populations):

  • Pregnancy and Lactation: Use is contraindicated during pregnancy and in women who are breastfeeding. Women of childbearing potential should use effective contraception.
  • Active Liver Disease: Patients with active liver disease, including unexplained, persistent elevations of serum transaminase enzymes (liver enzymes), must not use this medicine.
  • Hypersensitivity: Patients with a known allergy or hypersensitivity to any component of the product.

Conditional and Restricted Use:

Population/Condition Regulatory Constraint
Severe Renal Impairment (CrCl <30 mL/min) Use is either contraindicated or strictly limited to a maximum dose (e.g., 10 mg/day).
Asian Patients Lower starting dose (e.g., 5 mg) should be considered; the 40 mg dose is contraindicated.
Risk Factors for Myopathy The 40 mg dose is contraindicated in patients with hypothyroidism, hereditary muscular disorders, and other predisposing factors.
Pediatric Patients Eligibility is restricted by age (e.g., generally 6–8 years and older) and is limited to specific diagnoses like Familial Hypercholesterolemia.

These official rules classify populations into absolute exclusions, restricted-use groups, and groups where use is not established due to insufficient data, ensuring use remains within officially verified safety parameters.

What should I know about interactions with other medicines?

Rustor Interactions with Other Medicines and Products

Rustor (Rosuvastatin Calcium) has an official interaction profile primarily determined by its transport and clearance pathways, as documented by regulatory agencies.


Interaction Scope and Restrictions

The most significant interactions involve medicines that substantially increase Rosuvastatin exposure, mainly by inhibiting key hepatic uptake (OATP1B1) and efflux (BCRP) drug transporters. This results in mandated restrictions on co-administration.

Classification Interacting Agents (Examples) Official Regulatory Constraint
High-Risk Combination (Avoid/Not Recommended) Gemfibrozil, Sofosbuvir/velpatasvir/voxilaprevir Concomitant use should be avoided or is not recommended due to heightened toxicity risk.
Exposure-Increasing Agents (Transporter Inhibition) Cyclosporine, Lopinavir/Ritonavir, Capmatinib Mandatory dose restrictions apply to Rosuvastatin to limit systemic exposure.
Pharmacodynamic Reinforcement Fibrates, high-dose Niacin (ge 1 g/day) Increase the risk of myopathy/rhabdomyolysis (skeletal muscle effects).

Official Procedural and Population Notes

Rosuvastatin also interacts with oral anticoagulants, such as Warfarin, by affecting the coagulation system. This requires frequent monitoring of the International Normalized Ratio (INR) upon starting or adjusting the Rosuvastatin dose. Concerning products that interfere with absorption, combination antacids containing Aluminum and Magnesium Hydroxide must be administered at least two hours after Rosuvastatin to prevent a reduction in its plasma concentration. Additionally, regulatory documents note that Asian patients may have higher Rosuvastatin exposure, leading to a specific cautionary recommendation for a lower starting dose in this population.

Mechanism of Action

The mechanism of Rustor (Rosuvastatin) centers on two primary, interconnected biological domains that regulate the body's cholesterol balance and systemic vascular processes.


Enzyme Inhibition and Enhanced Hepatic Clearance

The drug's primary action involves the competitive inhibition of the enzyme HMG-CoA Reductase in the liver . This blockage curtails the internal synthesis of cholesterol via the Mevalonate pathway, which subsequently triggers a vital compensatory cascade: the significant upregulation of LDL Receptors on the surface of liver cells. This mechanistic sequence increases the liver's capacity to actively remove Low-Density Lipoprotein Cholesterol (LDL-C) and other lipoproteins from the bloodstream, resulting in a reduction in their circulating levels.


Modulation of Vascular Signaling Pathways

The mechanism of Rosuvastatin also involves secondary (pleiotropic) effects by interfering with the synthesis of isoprenoid intermediates within the affected pathway. This molecular interference modulates the function of certain GTP-binding proteins, leading to improved endothelial function and the dampening of systemic inflammatory markers. This mechanism influences the stability of the vascular endothelium and the modulation of systemic inflammation.

Dosage and Administration Information

Official Dosing and Administration Guidelines

Rustor (Rosuvastatin Calcium) is administered orally as a single dose once daily, available in film-coated tablets or capsules in strengths of 5 mg, 10 mg, 20 mg, and 40 mg. The medication may be taken at any time of day, with or without food. To ensure consistent delivery, tablets must be swallowed whole and should not be crushed or split.


Standard Regimen and Titration

The typical adult dosage range is 5 mg to 40 mg once daily. The usual starting dose is 10 mg or 20 mg. The maximum recommended dose is 40 mg, which is reserved for patients who have not achieved treatment goals on the 20 mg dose. Following treatment initiation or dose change, lipid levels should be assessed, and adjustments made, at intervals of 2 to 4 weeks.

If a daily dose is missed, patients should skip the missed dose and resume the normal daily schedule with the next dose; no extra dose should be taken.


Population-Specific Dosing Rules

Specific dose modifications apply to certain populations:

Patient Group Starting Dose and Maximum Limit
Asian Patients Initiate at 5 mg once daily; limit dose to 20 mg once daily.
Severe Renal Impairment Initiate at 5 mg once daily; do not exceed 10 mg once daily.
Concomitant Cyclosporine Use Do not exceed 5 mg once daily.

The 40 mg dose is not suitable for use in patients with moderate or severe renal impairment. Additionally, when taking an aluminum and magnesium hydroxide combination antacid, Rustor should be administered at least 2 hours before the antacid.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rustor

This text summarizes the research structure for Rustor (Rosuvastatin), focusing on the scope of studies conducted. This information describes what was evaluated and does not offer medical advice or predict individual outcomes.


Evidence for Managing High Cholesterol and Lipids

Research for this indication was studied for outcomes related to systemic or functional imbalance caused by high cholesterol. These studies often involved short-term, randomized controlled trials (RCTs) used in research exploring how key blood fat measurements—such as LDL-C and Total Cholesterol—change over time. The trials typically included adults with primary hypercholesterolemia, and some trials also examined pediatric patients with severe, inherited forms of the condition.

Studies report how symptoms evolved in the observed populations by describing measured patterns of LDL-C and Total Cholesterol measurements. The findings describe patterns observed in the studies where higher doses corresponded to a greater magnitude of measured change. Data for certain groups remain insufficient regarding the most appropriate high-dose usage in pediatric patients.


Evidence for Reducing the Risk of Heart and Vascular Events

Research examining major heart and vascular events was evaluated in large-scale, long-term randomized trials. These studies monitored populations of high-risk adults who had not yet experienced a heart attack or stroke but showed specific risk factors. The studies applied in research examining clinical outcomes like non-fatal heart attack, non-fatal stroke, and the need for revascularization procedures.

Research describes patterns observed during the study period, including measurements related to the frequency of these combined events in the group that was observed in the studies compared to the control group. The results apply only to the populations studied. Comparative evidence is lacking for directly comparing the primary prevention effect against all other high-potency statins.


What Research Remains Uncertain

This section synthesizes the areas where the current evidence base is limited. Sample sizes were modest in certain subgroup analyses. Subgroup findings are uncertain for many different populations that were not the primary focus of the main randomized trials. While research provides insight into short-term changes, long-term effects are not fully established across all measured outcomes. This research provides context but not individual predictions, and certainty remains low in areas where follow-up durations were limited.

Frequently Asked Questions (FAQ)

Common questions about Rustor (FAQ)

Q: What is Rustor?

Rustor is a prescription medication that belongs to a class of drugs called HMG-CoA reductase inhibitors, commonly known as statins. It is used to lower high levels of low-density lipoprotein (LDL) cholesterol (often called "bad" cholesterol) and triglycerides in the blood, while also increasing high-density lipoprotein (HDL) cholesterol (often called "good" cholesterol).

Rustor is used alongside diet and exercise to treat primary hyperlipidemia (high cholesterol) and mixed dyslipidemia, and to reduce the risk of certain cardiovascular events like heart attack and stroke in adults with specific risk factors.

Q: How should I take Rustor?

Rustor is typically taken once daily by mouth, with or without food, at the same time each day, as directed by your healthcare provider. The tablet should be swallowed whole. It's important to not crush, chew, or split the tablet.

  • Your doctor will determine the correct dose for you based on your cholesterol levels, medical condition, and response to treatment.
  • Do not stop taking Rustor, even if you feel well, unless your doctor tells you to. High cholesterol often has no symptoms.
  • If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at the same time.

Q: What are the common side effects of Rustor?

Like all medications, Rustor can cause side effects, although not everyone experiences them. Common side effects may include:

  • Headache
  • Muscle pain (myalgia)
  • Joint pain (arthralgia)
  • Nausea, abdominal pain, or diarrhea
  • Weakness or fatigue

Contact your healthcare provider if these side effects are persistent or bothersome. Your doctor may need to adjust your dose or recommend supportive care.

Q: Can Rustor interact with other medications?

Yes, Rustor can interact with several other medications, which may increase the risk of side effects, particularly serious muscle problems (rhabdomyolysis).

It is critical to tell your doctor about all prescription and non-prescription medicines, vitamins, and herbal supplements you are currently taking, especially:

  • Fibrates (e.g., gemfibrozil, fenofibrate)
  • Immunosuppressants (e.g., cyclosporine)
  • Certain antifungals (e.g., itraconazole, ketoconazole)
  • Certain macrolide antibiotics (e.g., erythromycin, clarithromycin)
  • HIV protease inhibitors (e.g., atazanavir, ritonavir)
  • Niacin (nicotinic acid)
  • Colchicine

Grapefruit juice can also interact with Rustor, so consult your healthcare provider about consuming grapefruit products while on this medication.

Q: Can I take Rustor if I am pregnant or breastfeeding?

No. Rustor is typically contraindicated (should not be used) during pregnancy and breastfeeding.

  • Pregnancy: Rustor may harm the developing fetus. If you become pregnant while taking Rustor, stop the medication immediately and contact your doctor.
  • Breastfeeding: It is not known if Rustor passes into breast milk, but because of the potential for serious adverse effects on a nursing infant, women should not breastfeed while taking this medicine.

Effective contraception should be used by women of childbearing potential during treatment with Rustor.

How should Rustor be stored and disposed of?

How to Store and Dispose of Rustor (Rosuvastatin Calcium)

Official regulatory documents define specific conditions for the storage and disposal of Rustor tablets.

Storage Requirements

Rustor must be stored at controlled room temperature, maintained between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. It is essential to protect the medication from moisture by keeping it in the original container or blister packaging until the time of use. As a standard safety precaution, the product must be kept out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Rustor must be disposed of safely and correctly according to local and national regulations for pharmaceutical waste. Patients are advised to follow any specific disposal instructions provided in the medication guide, often involving authorized drug take-back programs, to prevent the product from entering household waste or water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rustor found in:

A-Z Index: